Leukocytes

Vor Biopharma Closes $110 Million Series B Financing

Retrieved on: 
Tuesday, July 7, 2020
Oncology, Professional services, Health, Stem cells, Finance, Pharmaceutical, Biotechnology, Branches of biology, Stem cells, Life sciences, Companies, Hematopoietic stem cell, Leukocytes, Johnson & Johnson, Vor Biopharma, VOR33

Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced it has raised $110 million in a Series B financing.

Key Points: 
  • Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced it has raised $110 million in a Series B financing.
  • RA Capital Management led the Series B financing, along with a diverse group of well-respected new investors including Fidelity Management & Research Company, LLC, Pagliuca Family Office, Alexandria Venture Investments, and other undisclosed investors, including additional institutional crossover investors.
  • Existing investors 5AM Ventures, Johnson & Johnson Innovation JJDC, Inc. (JJDC), Osage University Partners, and co-founder PureTech Health participated in the financing.
  • Vor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies.

Peripheral Blood Mononuclear Cells (PBMCs) Market by Product, Application, Technique, Source and Region - Forecast to 2025

Retrieved on: 
Wednesday, June 17, 2020
Leukocytes, Peripheral blood mononuclear cell, Agranulocyte, CCL17

DUBLIN, June 17, 2020 /PRNewswire/ -- The "Global Peripheral Blood Mononuclear Cells Market By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, Peripheral Blood Mononuclear Cell Isolation & Viability Kits), By Application, By Technique, By Source, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 17, 2020 /PRNewswire/ -- The "Global Peripheral Blood Mononuclear Cells Market By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, Peripheral Blood Mononuclear Cell Isolation & Viability Kits), By Application, By Technique, By Source, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.
  • The Global Peripheral Blood Mononuclear Cells Market is expected to grow at a steady CAGR during the forecast period.
  • The peripheral blood mononuclear cells (PBMCs) are crucial to carry out the biology and pathology related studies as well as in clinical research related to cancer.
  • The product segment is further divided into cryopreserved or frozen PBMC, cultured or fresh PBMC and peripheral blood mononuclear cell isolation & viability kits.

BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention

Retrieved on: 
Monday, June 15, 2020
Medical specialties, Branches of biology, Anatomy, Recombinant proteins, Blood, Leukocytes, Neutropenia, Pegfilgrastim

The interim results have shown significant enhancement of the combination over Neulasta in the rate of Grade 4 neutropenia prevention (p

Key Points: 
  • The interim results have shown significant enhancement of the combination over Neulasta in the rate of Grade 4 neutropenia prevention (p
  • The PROTECTIVE-2 Phase 3 study is a double-blind, active controlled, global trial, with the pre-specified interim analysis at approximately 120 patients accrued.
  • The interim results also met its key secondary endpoint, the duration of severe neutropenia (DSN) in Cycle 1 (p
  • We are extremely excited about the topline results from the interim analysis of PROTECTIVE-2 Phase 3.

Global Peripheral Blood Mononuclear Cells Markets, 2015-2019 & 2020-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 11, 2020
Health, Other Health, Leukocytes, Peripheral blood mononuclear cell, Agranulocyte, Visceral leishmaniasis, CCL17

The "Global Peripheral Blood Mononuclear Cells Market By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, Peripheral Blood Mononuclear Cell Isolation & Viability Kits), By Application, By Technique, By Source, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Peripheral Blood Mononuclear Cells Market By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, Peripheral Blood Mononuclear Cell Isolation & Viability Kits), By Application, By Technique, By Source, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.
  • The Global Peripheral Blood Mononuclear Cells Market is expected to grow at a steady CAGR during the forecast period.
  • The peripheral blood mononuclear cells (PBMCs) are crucial to carry out the biology and pathology related studies as well as in clinical research related to cancer.
  • The product segment is further divided into cryopreserved or frozen PBMC, cultured or fresh PBMC and peripheral blood mononuclear cell isolation & viability kits.

Neutropenia Treatment Market to Garner $19.30 Bn, Globally, by 2027 at 5.4% CAGR, Says Allied Market Research

Retrieved on: 
Monday, June 8, 2020
Life sciences, Medical specialties, Medicine, Blood disorders, Biotechnology, Blood, Leukocytes, Neutropenia, Biosimilar

Rise in prevalence of leukemia, surge in R&D efforts and development of new drugs, and fundamental shift from branded drugs to biosimilars in cancer supportive treatment drive the global neutropenia treatment market.

Key Points: 
  • Rise in prevalence of leukemia, surge in R&D efforts and development of new drugs, and fundamental shift from branded drugs to biosimilars in cancer supportive treatment drive the global neutropenia treatment market.
  • However, high cost of the treatment of neutropenia and stringent rules for product approvals hamper the market growth.
  • On the contrary, robust drug pipeline for neutropenia treatment would open new opportunities for the market players in the coming years.
  • By region, the global neutropenia treatment market across North America held the largest share in 2019, accounting for nearly half of the market.

Neutropenia Treatment Market to Garner $19.30 Bn, Globally, by 2027 at 5.4% CAGR, Says Allied Market Research

Retrieved on: 
Monday, June 8, 2020
Life sciences, Medical specialties, Medicine, Blood disorders, Biotechnology, Blood, Leukocytes, Neutropenia, Biosimilar

Rise in prevalence of leukemia, surge in R&D efforts and development of new drugs, and fundamental shift from branded drugs to biosimilars in cancer supportive treatment drive the global neutropenia treatment market.

Key Points: 
  • Rise in prevalence of leukemia, surge in R&D efforts and development of new drugs, and fundamental shift from branded drugs to biosimilars in cancer supportive treatment drive the global neutropenia treatment market.
  • However, high cost of the treatment of neutropenia and stringent rules for product approvals hamper the market growth.
  • On the contrary, robust drug pipeline for neutropenia treatment would open new opportunities for the market players in the coming years.
  • By region, the global neutropenia treatment market across North America held the largest share in 2019, accounting for nearly half of the market.

CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program

Retrieved on: 
Friday, May 29, 2020
Autoimmune diseases, Anatomy, Blood, Leukocytes, Neutropenia, Medical specialties, Branches of biology

CX-2029 is conjugated to the cytotoxic payload MMAE and is being developed by CytomX in partnership with AbbVie.

Key Points: 
  • CX-2029 is conjugated to the cytotoxic payload MMAE and is being developed by CytomX in partnership with AbbVie.
  • 2 of the partial responses (both at the 3 mg/kg dose) were confirmed after the April 20th cutoff date.
  • No CX-2029 treatment related deaths were reported and late onset Grade 3/4 TRAEs were predominately anemia and neutropenia.
  • CytomX continues to closely monitor emerging Health Authority guidance and IRB/Ethics Committee recommendations and intends to resume the CX-2009 clinical program as soon as practicable.

Vor Biopharma Adds to Leadership Team with Appointment of Chief Financial Officer

Retrieved on: 
Tuesday, May 26, 2020
Oncology, Professional services, Health, Stem cells, Finance, Pharmaceutical, Biotechnology, Stem cells, Hematopoietic stem cell, Leukocytes, Vor Biopharma, VOR33

Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of Nathan Jorgensen, PhD, as Chief Financial Officer.

Key Points: 
  • Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of Nathan Jorgensen, PhD, as Chief Financial Officer.
  • Nathan is a rare combination of financial analyst and scientist and brings these valuable skills to Vor at an important time in our development as company, said Robert Ang, MBBS, MBA, Vors President and Chief Executive Officer.
  • Dr. Jorgensen brings a comprehensive background of buy-side, sell-side, consulting, and scientific experience to his new role at Vor.
  • Vor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies.

Inhibitory Effect of Innovation Pharmaceuticals’ Brilacidin on SARS-CoV-2 (COVID-19) in Primary Human Immune Cells to be Studied at Leading Public Health Research Institute

Retrieved on: 
Tuesday, May 5, 2020
Branches of biology, Immune system, Leukocytes, Cell biology, Connective tissue cells, Animal virology, Macrophage, Severe acute respiratory syndrome-related coronavirus, Middle East respiratory syndrome-related coronavirus, Coronavirus, Monocyte, Agranulocyte

Regional Biocontainment Laboratory (RBL), which over the weekend informed us that the next phase of Brilacidin testing has commenced.

Key Points: 
  • Regional Biocontainment Laboratory (RBL), which over the weekend informed us that the next phase of Brilacidin testing has commenced.
  • Scientists at the Public Health Research Institute plan to evaluate Brilacidins inhibitory effect on SARS-CoV-2 viral replication in primary immune mediators (peripheral blood mononuclear cells, T cells, B cells, monocytes, macrophages) obtained from both young and old donors to assess age-dependent host responses to the novel coronavirus.
  • Brilacidin drug substance has been received by the Institute and is now available for testing.
  • The Company appreciates the support and interest in Brilacidin from these government-funded laboratories during the COVID-19 pandemic.

Global Chemotherapy Induced Neutropenia (CIN) Pipeline Insight, 2020: Current Clinical Development Scenario and Future Growth Prospects - ResearchAndMarkets.com

Retrieved on: 
Friday, May 1, 2020
Pharmaceutical, Health, Oncology, Medicine, Clinical medicine, Cancer, Oncology, Cancer treatments, Blood, Leukocytes, Neutropenia, Chemotherapy, Cancer staging, Eflapegrastim

Chemotherapy Induced Neutropenia (CIN) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Chemotherapy Induced Neutropenia (CIN) market.

Key Points: 
  • Chemotherapy Induced Neutropenia (CIN) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Chemotherapy Induced Neutropenia (CIN) market.
  • A detailed picture of the Chemotherapy Induced Neutropenia (CIN) pipeline landscape is provided, which includes the disease overview and Chemotherapy Induced Neutropenia (CIN) treatment guidelines.
  • The assessment part of the report embraces in-depth Chemotherapy Induced Neutropenia (CIN) commercial assessment and clinical assessment of the Chemotherapy Induced Neutropenia (CIN) pipeline products from the pre-clinical developmental phase to the marketed phase.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Chemotherapy Induced Neutropenia (CIN) treatment.